Fig. 10

Therapeutic targeting of tumor vasculature to enhance anticancer activity. Inhibition of VEGF and/or VEGFR is the most used antiangiogenic strategy accomplished with several FDA-approved agents, such as anti-VEGF and VEGF-TRAP (VEGF decoy receptors), and/or VEGFR-specific antibodies and tyrosine kinase inhibitors (RTK inhibitors), respectively. Alternatively, ANG2-TIE2 inhibitors currently being tested in the clinic can also be used to promote antiangiogenesis. The drugs targeting tumor vasculature, either FDA-approved or being-evaluated at different stages of clinical development drugs, are referenced in the text. VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; ANG2: Angiopoietin-2; TIE2: TEK receptor tyrosine kinase; TKIs: Tyrosine kinase inhibitors. TME: Tumor microenvironment. This figure has been created with BioRender.com